Study identifies ‚lethal‘ subtype of prostate cancer

Of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death, a study concludes. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions. (Mehr in: Cancer News — ScienceDaily)